Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Wysham · SciRah

Researcher profile · Semantic Scholar

C. Wysham

Share profile

C. Wysham — researcher profile on SciRah

h-index: 25
Works: 100
Citations: 3,969

Most-cited papers

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
J. Rosenstock, C. Wysham, J. Frias, Shizuka Kaneko +6 more
2021The Lancet769 citations
Semantic Scholar
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
R. Bergenstal, C. Wysham, L. Macconell, Jaret Malloy +5 more
2010The Lancet619 citations
Semantic Scholar
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial
V. Aroda, J. Rosenstock, C. Wysham, J. Unger +7 more
2016Diabetes Care261 citations
Semantic Scholar
Erratum. Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care 2014;37:2159–2167
C. Wysham, T. Blevins, R. Arakaki, G. Colon +4 more
2014Diabetes Care240 citations Open access
Semantic Scholar
Age-related changes in the circadian rhythm of plasma cortisol in man.
B. Sherman, C. Wysham, B. Pfohl
1985Journal of Clinical Endocrinology and Metabolism226 citations
Semantic Scholar
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial
C. Wysham, A. Bhargava, L. Chaykin, R. E. de la Rosa +4 more
2017Journal of the American Medical Association (JAMA)223 citations Open access
Semantic Scholar
Beta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications
C. Wysham, J. Shubrook
2020Postgraduate medicine183 citations Open access
Semantic Scholar
Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
C. Wysham, T. Blevins, R. Arakaki, G. Colon +4 more
2014Diabetes Care149 citations
Semantic Scholar
Diabetes Performance Measures: Current Status and Future Directions
P. O'Connor, N. Bodkin, J. Fradkin, R. Glasgow +8 more
2011Diabetes Care141 citations Open access
Semantic Scholar
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
C. D. De Block, C. Bailey, C. Wysham, A. Hemmingway +2 more
2022Diabetes, obesity and metabolism108 citations Open access
Semantic Scholar
Efficacy and safety of canagliflozin when used in conjunction with incretin‐mimetic therapy in patients with type 2 diabetes
G. Fulcher, D. Matthews, V. Perkovic, D. de Zeeuw +10 more
2016Diabetes, obesity and metabolism85 citations Open access
Semantic Scholar
GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date
S. Brunton, C. Wysham
2020Postgraduate medicine68 citations Open access
Semantic Scholar
TWO TREATMENT APPROACHES FOR HUMAN REGULAR U-500 INSULIN IN PATIENTS WITH TYPE 2 DIABETES NOT ACHIEVING ADEQUATE GLYCEMIC CONTROL ON HIGH-DOSE U-100 INSULIN THERAPY WITH OR WITHOUT ORAL AGENTS: A RANDOMIZED, TITRATION-TO-TARGET CLINICAL TRIAL.
R. Hood, R. Arakaki, C. Wysham, Y. Li +2 more
2015Endocrine Practice56 citations
Semantic Scholar
Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.
C. Wysham, L. Macconell, D. Maggs, Ming Zhou +2 more
2015Mayo Clinic proceedings54 citations
Semantic Scholar
Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data
James B. Young, M. Gauthier-Loiselle, R. Bailey, A. Manceur +6 more
2018Cardiovascular Diabetology38 citations Open access
Semantic Scholar
Diabetes performance measures: Current status and future directions (Diabetes Care (2011) 34, (1651-1659))
P. O'Connor, N. Bodkin, J. Fradkin, R. Glasgow +8 more
201137 citations Open access
Semantic Scholar
Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes
C. Wysham, J. Rosenstock, M. Vetter, Fang Dong +2 more
2017Diabetes, obesity and metabolism34 citations Open access
Semantic Scholar
Once weekly exenatide: efficacy, tolerability and place in therapy
C. Wysham, Michael Grimm, S. Chen
2013Diabetes, obesity and metabolism32 citations
Semantic Scholar
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed‐ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan‐L trial
C. Wysham, R. Bonadonna, V. Aroda, M. Puig Domingo +6 more
2017Diabetes, obesity and metabolism31 citations Open access
Semantic Scholar
Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes*
C. Wysham, C. Lush, Bei Zhang, Holly Maier +1 more
2008Current Medical Research and Opinion31 citations
Semantic Scholar
Practical Guidance on Effective Basal Insulin Titration for Primary Care Providers
L. Kuritzky, Timothy S. Reid, C. Wysham
2019Clinical Diabetes30 citations Open access
Semantic Scholar
Development of a preliminary diabetes dietary satisfaction and outcomes measure for patients with type 2 diabetes
S. Ahlgren, J. Shultz, L. Massey, B. Hicks +1 more
2004Quality of Life Research30 citations
Semantic Scholar
Circulating dendritic cell number and intracellular TNF-α production in women with type 2 diabetes
S. E. Blank, E. Johnson, Deborah K. Weeks, C. Wysham
2012Acta Diabetologica28 citations
Semantic Scholar
New Perspectives in Type 2 Diabetes, Cardiovascular Risk, and Treatment Goals
C. Wysham
2010Postgraduate medicine28 citations
Semantic Scholar
Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis
C. Wysham, Jay Lin, L. Kuritzky
2017Postgraduate medicine25 citations
Semantic Scholar
Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis
Á. Tabák, John E. Anderson, P. Aschner, Min-Zhi Liu +5 more
2019Diabetes Therapy24 citations Open access
Semantic Scholar
Effects of Extended Release Niacin added to Simvastatin/Ezetemibe on Glucose and Insulin values in AIM HIGH
R. Goldberg, V. Bittner, Richard L. Dunbar, J. Fleg +9 more
2016American Journal of Medicine24 citations Open access
Semantic Scholar
EFFECT OF TOTAL DAILY DOSE ON EFFICACY, DOSING, AND SAFETY OF 2 DOSE TITRATION REGIMENS OF HUMAN REGULAR U500 INSULIN IN SEVERELY INSULIN-RESISTANT PATIENTS WITH TYPE 2 DIABETES.
C. Wysham, R. Hood, M. Warren, Tao Wang +2 more
2016Endocrine Practice23 citations
Semantic Scholar
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis
P. Rossing, G. Bakris, V. Perkovic, R. Pratley +395 more
2025Diabetes Care22 citations Open access
Semantic Scholar
Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study.
A. Philis-Tsimikas, C. Wysham, É. Hardy, Jenny Han +1 more
2019Journal of diabetes and its complications22 citations Open access
Semantic Scholar
DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide
C. Wysham, R. Bergenstal, Jaret Malloy, P. Yan +3 more
2011Diabetic Medicine22 citations Open access
Semantic Scholar
Baseline factors associated with glycaemic response to treatment with once‐weekly dulaglutide in patients with type 2 diabetes
C. Wysham, B. Guerci, D. D'Alessio, N. Jia +1 more
2016Diabetes, obesity and metabolism20 citations
Semantic Scholar
Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus
N. Freemantle, D. Mauricio, A. Giaccari, T. Bailey +16 more
2019Current Medical Research and Opinion19 citations Open access
Semantic Scholar
Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications
C. Wysham, C. Campos, D. Kruger
2018Clinical Diabetes18 citations Open access
Semantic Scholar
Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2
S. Heller, J. H. DeVries, C. Wysham, Charlotte T. Hansen +2 more
2019Diabetes, obesity and metabolism17 citations Open access
Semantic Scholar
Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes
O. Schnell, T. Battelino, R. Bergenstal, M. Blüher +26 more
2022Cardiovascular Diabetology15 citations Open access
Semantic Scholar
Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes
G. Oster, S. Sullivan, M. Dalal, M. Kazemi +11 more
2016Postgraduate medicine15 citations Open access
Semantic Scholar
Efficacy and Safety of Multiple Doses of Exenatide Once-Monthly Suspension in Patients With Type 2 Diabetes: A Phase II Randomized Clinical Trial
C. Wysham, L. Macconell, É. Hardy
2016Diabetes Care14 citations
Semantic Scholar
HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
C. Wysham, D. Pilon, M. Ingham, M. Lafeuille +4 more
2018Endocrine Practice13 citations
Semantic Scholar
Imipramine effect on hypothalamic-pituitary-adrenal axis response to hypoglycemia.
R. Kathol, R. Jaeckle, C. Wysham, B. Sherman
1992Psychiatry Research12 citations
Semantic Scholar
The Impact of Web-Based Continuing Medical Education Using Patient Simulation on Real-World Treatment Selection in Type 2 Diabetes: Retrospective Case-Control Analysis
K. Lucero, A. Larkin, Stanislav Zakharkin, C. Wysham +1 more
2023JMIR Medical Education11 citations Open access
Semantic Scholar
Development of risk models for major adverse chronic renal outcomes among patients with type 2 diabetes mellitus using insurance claims: a retrospective observational study
C. Wysham, M. Gauthier-Loiselle, R. Bailey, A. Manceur +4 more
2020Current Medical Research and Opinion11 citations
Semantic Scholar
Canagliflozin (CANA) Added on to Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) or Glucagon-like Peptide-1 (GLP-1) Agonists with or Without Other Antihyperglycemic Agents (AHAs) in Type 2 Diabetes Mellitus (T2DM)
V. Woo, C. Wysham, C. Mathieu, Mehul Desai +3 more
201310 citations Open access
Semantic Scholar
Current issues in GLP-1 receptor agonist therapy for type 2 diabetes.
Z. Bloomgarden, L. Blonde, A. Garber, C. Wysham
2012Endocrine Practice10 citations
Semantic Scholar
Update on Insulin Management in Type 2 Diabetes
J. Neumiller, P. Odegard, C. Wysham
2009Diabetes Spectrum10 citations Open access
Semantic Scholar
Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting
C. Wysham, D. Pilon, M. Ingham, M. Lafeuille +4 more
2018Current Medical Research and Opinion9 citations
Semantic Scholar
Evaluation of the Use of Exenatide Once-Weekly Suspension Autoinjector Among Patients With Type 2 Diabetes Mellitus and Health Care Professionals
S. LaRue, J. Springer, Michael Noderer, J. Meehan +1 more
2018Journal of Diabetes Science and Technology9 citations Open access
Semantic Scholar
Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972–1980
V. Aroda, J. Rosenstock, C. Wysham, J. Unger +7 more
2017Diabetes Care9 citations Open access
Semantic Scholar
Efficacy and Safety of Dulaglutide Versus Placebo and Exenatide in Type 2 Diabetes (AWARD-1)
C. Wysham, T. Blevins, R. Arakaki, G. Colon +5 more
20139 citations
Semantic Scholar
Practical Considerations for Initiating and Utilizing Flash Continuous Glucose Monitoring in Clinical Practice
C. Wysham, D. Kruger
2021Journal of the Endocrine Society6 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Bergenstal×5
Invite
R. Bergenstal — researcher profile on SciRah
J. Rosenstock×4
Invite
J. Rosenstock — researcher profile on SciRah
V. Aroda×4
Invite
V. Aroda — researcher profile on SciRah
R. Arakaki×4
Invite
R. Arakaki — researcher profile on SciRah

×4

Invite

P. Lefebvre — researcher profile on SciRah

L. Macconell×3

Invite

L. Macconell — researcher profile on SciRah

E. Niemoeller×3

Invite

E. Niemoeller — researcher profile on SciRah

Invite

E. Souhami — researcher profile on SciRah

Invite

T. Blevins — researcher profile on SciRah

Invite

G. Colon — researcher profile on SciRah

Invite

P. García — researcher profile on SciRah

Invite

C. Atisso — researcher profile on SciRah